Application of dopamine d1 receptor antagonist sch39166 as a drug for the treatment of ocular pathological angiogenesis
A technology of SCH39166 and receptor antagonists, which is applied in the field of new applications of SCH39166, can solve the problems of unsustainable effect, short maintenance time, damage to vision, etc. effect of disease
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0016] SCH39166 inhibits retinal angiogenesis in oxygen-induced retinal injury
[0017] Littermate C57BL / 6 mice were fed in a 75% hyperoxic environment for 5 days, then moved to a normal oxygen environment on P12 and continued to be fed. From P12, intraperitoneal administration was started, and samples were collected until P17. In the relative hypoxic phase, the SCH39166 drug treatment group had a significantly increased retinal non-perfusion area compared with its solvent DMSO control group (DMSO vs SCH: 13.71% ± 2.64% vs 18.73% ± 3.56%, P = 0.0111, independent t- test), while the area of pathological neovascularization was significantly reduced (DMSO vs SCH39166: 4.40% ± 1.24% vs 2.29% ± 0.83%, P = 0.0030, independent t-test) ( figure 1 ). demonstrated that DRD1 antagonists inhibited pathological neovascularization during the relatively hypoxic phase of the OIR model.
[0018] SCH39166 inhibits laser-induced choroidal angiogenesis
[0019] C57BL / 6 mice aged 8-10 weeks w...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com